Trial Information

Summary: A Randomized Phase III Study of Paclitaxel + Cisplatin versus Vinorelbine + Cisplatin versus Gemcitabine + Cisplatin versus Topotecan + Cisplatin in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix [GOG0204]

This is research study for women who have a malignant cervical tumor which cannot be cured by surgery or radiation therapy. The purpose of this research study is to determine the best chemotherapy drug to be given with cisplatin. Chemotherapy with cisplatin and paclitaxel is the standard treatment for cancer of the cervix in this situation. The study drugs used in this study are vinorelbine, gemcitabine and topotecan. Study participants have an equal chance of being placed in any one of the following 4 groups:
1) cisplatin + paclitaxel
2) cisplatin + vinorelbine
3) cisplatin + gemcitabine
4) cisplatin + topotecan

No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are 18 years of age or older
-have been diagnosed with a malignant cervical tumor which cannot be cured by surgery or radiation therapy
-meet additional criteria

You are not eligible for this study if you
-are pregnant or breastfeeding
-currently have another type of cancer other than skin cancer
-have been previously treated with chemotherapy except when used in addition to radiation therapy

If you would like to learn more about participating in this study, please send an e-mail message using the form below.